{"id":320321,"date":"2025-11-26T18:04:14","date_gmt":"2025-11-26T18:04:14","guid":{"rendered":"https:\/\/peraltafinancing.com\/uncategorized\/quantifying-treatment-value-under-ira-healthcare-economist\/"},"modified":"2025-11-26T18:04:14","modified_gmt":"2025-11-26T18:04:14","slug":"quantifying-treatment-value-under-ira-healthcare-economist","status":"publish","type":"post","link":"https:\/\/fivemor.com\/?p=320321","title":{"rendered":"Quantifying treatment value under IRA \u2013 Healthcare Economist"},"content":{"rendered":"<p> <br \/>\n<\/p>\n<div>\n<p>That is the title of my new publication out today with the subtitle \u201c<a href=\"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2025.2587415#abstract\">A case study of rifaximin for the treatment of overt hepatic encephalopathy using QALY and non-QALY measures<\/a>\u201c.  This was work with co-authors Shanshan Wang, Leonardo Passos Chaves, Olamide Olujohungbe, Sanjana Muthukrishnan, and Aditi Chaudhary. The abstract is below. <\/p>\n<blockquote class=\"wp-block-quote\">\n<p> <strong>Background<\/strong><br \/>Traditional cost effectiveness analyses frequently use quality-adjusted life years (QALYs) to quantify health benefits. The Medicare Drug Price Negotiation program, however, cannot use QALYs, but may consider alternative, non-discriminatory metrics.<br \/><strong>Objective<\/strong><br \/>To examine the impact of using alternative quantitative health benefit metrics on the economic value of new medications. The framework was applied to assess the cost-effectiveness of rifaximin for preventing overt hepatic encephalopathy (OHE) recurrence in adults.<br \/><strong>Methods<\/strong><br \/>A cost-effectiveness analysis evaluated the economic value of rifaximin\u2009\u00b1\u2009lactulose versus standard of care\u2009\u00b1\u2009lactulose in preventing recurrent OHE in adults over a lifetime horizon from US payer and societal perspectives. Clinical outcomes included time in remission and overt health states, number of liver transplants, and life years (LYs). Health benefit was quantified using QALYs, health years in total (HYT), equal-value of life years gained (evLYG), and generalized risk-adjusted cost-effectiveness (GRACE). Treatment value was measured using incremental cost effectiveness ratio (ICER). A societal perspective scenario added productivity and caregiving impacts to the model.<br \/><strong>Results<\/strong><br \/>Rifaximin patients spent &gt;3 times as long in remission (54.4 vs. 17.3\u2009months), comparable time in the overt health state (1.44 vs. 1.44\u2009months), and had twice as many liver transplants (20 vs. 9), driven by longer survival (8.80 vs. 4.17 LYs), resulting in incremental gains of 3.12 QALYs, 3.26 HYT, 2.78 evLYG, and 3.16 GRA-QALYs. Total costs were higher with rifaximin ($182,369 vs. $38,313, \u0394\u2009=\u2009$144,056), mainly due to drug costs (\u0394\u2009=\u2009$133,330). Including caregiving and productivity reduced the incremental cost to $136,866. From a payer perspective, rifaximin ICERs were $46,215\/QALY, $44,198\/HYT, $51,847\/evLYG, and $45,609\/GRA-QALY. After incorporating societal costs, ICERs improved to $43,908\/QALY, $41,992\/HYT, $49,259\/evLYG, and $43,332\/GRA-QALY.<br \/><strong>Conclusion<\/strong><br \/>Rifaximin is a cost-effective treatment for preventing OHE recurrence in adults using QALY and non-QALY health benefit measures. <\/p>\n<\/blockquote>\n<p>You can read the full paper <strong><a href=\"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2025.2587415#abstract\">here<\/a><\/strong>.<\/p>\n<\/p><\/div>\n\n","protected":false},"excerpt":{"rendered":"<p>That is the title of my new publication out today with the subtitle \u201cA case study of rifaximin for the treatment of overt hepatic encephalopathy using QALY and non-QALY measures\u201c. This was work with co-authors Shanshan Wang, Leonardo Passos Chaves, Olamide Olujohungbe, Sanjana Muthukrishnan, and Aditi Chaudhary. The abstract is below. BackgroundTraditional cost effectiveness analyses [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[147831,139539,147832,147830,147833],"tags":[25861,4391,10973,70581,14368],"dealstore":[],"offerexpiration":[],"class_list":["post-320321","post","type-post","status-publish","format-standard","hentry","category-hepatology","category-ira","category-medicare-drug-price-negotiation","category-my-papers","category-rifaximin","tag-economist","tag-healthcare","tag-ira","tag-quantifying","tag-treatment"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Quantifying treatment value under IRA \u2013 Healthcare Economist - Som2ny Network<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/fivemor.com\/?p=320321\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Quantifying treatment value under IRA \u2013 Healthcare Economist - Som2ny Network\" \/>\n<meta property=\"og:description\" content=\"That is the title of my new publication out today with the subtitle \u201cA case study of rifaximin for the treatment of overt hepatic encephalopathy using QALY and non-QALY measures\u201c. This was work with co-authors Shanshan Wang, Leonardo Passos Chaves, Olamide Olujohungbe, Sanjana Muthukrishnan, and Aditi Chaudhary. The abstract is below. BackgroundTraditional cost effectiveness analyses [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/fivemor.com\/?p=320321\" \/>\n<meta property=\"og:site_name\" content=\"Som2ny Network\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-26T18:04:14+00:00\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/fivemor.com\/?p=320321#article\",\"isPartOf\":{\"@id\":\"https:\/\/fivemor.com\/?p=320321\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/fivemor.com\/#\/schema\/person\/b85e3c3dc0e1daea076524dc8810c371\"},\"headline\":\"Quantifying treatment value under IRA \u2013 Healthcare Economist\",\"datePublished\":\"2025-11-26T18:04:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/fivemor.com\/?p=320321\"},\"wordCount\":339,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/fivemor.com\/#organization\"},\"keywords\":[\"Economist\",\"healthcare\",\"IRA\",\"Quantifying\",\"Treatment\"],\"articleSection\":[\"Hepatology\",\"IRA\",\"Medicare Drug Price Negotiation\",\"My Papers\",\"Rifaximin\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/fivemor.com\/?p=320321#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/fivemor.com\/?p=320321\",\"url\":\"https:\/\/fivemor.com\/?p=320321\",\"name\":\"Quantifying treatment value under IRA \u2013 Healthcare Economist - Som2ny Network\",\"isPartOf\":{\"@id\":\"https:\/\/fivemor.com\/#website\"},\"datePublished\":\"2025-11-26T18:04:14+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/fivemor.com\/?p=320321#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/fivemor.com\/?p=320321\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/fivemor.com\/?p=320321#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/fivemor.com\/?bp_activities=1\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Quantifying treatment value under IRA \u2013 Healthcare Economist\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/fivemor.com\/#website\",\"url\":\"https:\/\/fivemor.com\/\",\"name\":\"Som2ny Network\",\"description\":\"Daily Deals\",\"publisher\":{\"@id\":\"https:\/\/fivemor.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/fivemor.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/fivemor.com\/#organization\",\"name\":\"Som2ny Network\",\"url\":\"https:\/\/fivemor.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/fivemor.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/fivemor.com\/wp-content\/uploads\/2026\/07\/4a0953c4-logo-300x86-1.png\",\"contentUrl\":\"https:\/\/fivemor.com\/wp-content\/uploads\/2026\/07\/4a0953c4-logo-300x86-1.png\",\"width\":300,\"height\":86,\"caption\":\"Som2ny Network\"},\"image\":{\"@id\":\"https:\/\/fivemor.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/fivemor.com\/#\/schema\/person\/b85e3c3dc0e1daea076524dc8810c371\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/fivemor.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/729ae85bf62b9917e93538db2f2688ca?s=96&r=g&default=https%3A%2F%2Ffivemor.com%2Fwp-content%2Fplugins%2Fbuddypress-first-letter-avatar%2Fimages%2Fdefault%2F96%2Flatin_a.png\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/729ae85bf62b9917e93538db2f2688ca?s=96&r=g&default=https%3A%2F%2Ffivemor.com%2Fwp-content%2Fplugins%2Fbuddypress-first-letter-avatar%2Fimages%2Fdefault%2F96%2Flatin_a.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/fivemor.com\"],\"url\":\"https:\/\/fivemor.com\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Quantifying treatment value under IRA \u2013 Healthcare Economist - Som2ny Network","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/fivemor.com\/?p=320321","og_locale":"en_US","og_type":"article","og_title":"Quantifying treatment value under IRA \u2013 Healthcare Economist - Som2ny Network","og_description":"That is the title of my new publication out today with the subtitle \u201cA case study of rifaximin for the treatment of overt hepatic encephalopathy using QALY and non-QALY measures\u201c. This was work with co-authors Shanshan Wang, Leonardo Passos Chaves, Olamide Olujohungbe, Sanjana Muthukrishnan, and Aditi Chaudhary. The abstract is below. BackgroundTraditional cost effectiveness analyses [&hellip;]","og_url":"https:\/\/fivemor.com\/?p=320321","og_site_name":"Som2ny Network","article_published_time":"2025-11-26T18:04:14+00:00","author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/fivemor.com\/?p=320321#article","isPartOf":{"@id":"https:\/\/fivemor.com\/?p=320321"},"author":{"name":"admin","@id":"https:\/\/fivemor.com\/#\/schema\/person\/b85e3c3dc0e1daea076524dc8810c371"},"headline":"Quantifying treatment value under IRA \u2013 Healthcare Economist","datePublished":"2025-11-26T18:04:14+00:00","mainEntityOfPage":{"@id":"https:\/\/fivemor.com\/?p=320321"},"wordCount":339,"commentCount":0,"publisher":{"@id":"https:\/\/fivemor.com\/#organization"},"keywords":["Economist","healthcare","IRA","Quantifying","Treatment"],"articleSection":["Hepatology","IRA","Medicare Drug Price Negotiation","My Papers","Rifaximin"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/fivemor.com\/?p=320321#respond"]}]},{"@type":"WebPage","@id":"https:\/\/fivemor.com\/?p=320321","url":"https:\/\/fivemor.com\/?p=320321","name":"Quantifying treatment value under IRA \u2013 Healthcare Economist - Som2ny Network","isPartOf":{"@id":"https:\/\/fivemor.com\/#website"},"datePublished":"2025-11-26T18:04:14+00:00","breadcrumb":{"@id":"https:\/\/fivemor.com\/?p=320321#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/fivemor.com\/?p=320321"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/fivemor.com\/?p=320321#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/fivemor.com\/?bp_activities=1"},{"@type":"ListItem","position":2,"name":"Quantifying treatment value under IRA \u2013 Healthcare Economist"}]},{"@type":"WebSite","@id":"https:\/\/fivemor.com\/#website","url":"https:\/\/fivemor.com\/","name":"Som2ny Network","description":"Daily Deals","publisher":{"@id":"https:\/\/fivemor.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/fivemor.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/fivemor.com\/#organization","name":"Som2ny Network","url":"https:\/\/fivemor.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/fivemor.com\/#\/schema\/logo\/image\/","url":"https:\/\/fivemor.com\/wp-content\/uploads\/2026\/07\/4a0953c4-logo-300x86-1.png","contentUrl":"https:\/\/fivemor.com\/wp-content\/uploads\/2026\/07\/4a0953c4-logo-300x86-1.png","width":300,"height":86,"caption":"Som2ny Network"},"image":{"@id":"https:\/\/fivemor.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/fivemor.com\/#\/schema\/person\/b85e3c3dc0e1daea076524dc8810c371","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/fivemor.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/729ae85bf62b9917e93538db2f2688ca?s=96&r=g&default=https%3A%2F%2Ffivemor.com%2Fwp-content%2Fplugins%2Fbuddypress-first-letter-avatar%2Fimages%2Fdefault%2F96%2Flatin_a.png","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/729ae85bf62b9917e93538db2f2688ca?s=96&r=g&default=https%3A%2F%2Ffivemor.com%2Fwp-content%2Fplugins%2Fbuddypress-first-letter-avatar%2Fimages%2Fdefault%2F96%2Flatin_a.png","caption":"admin"},"sameAs":["https:\/\/fivemor.com"],"url":"https:\/\/fivemor.com\/?author=1"}]}},"_links":{"self":[{"href":"https:\/\/fivemor.com\/index.php?rest_route=\/wp\/v2\/posts\/320321","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/fivemor.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/fivemor.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/fivemor.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/fivemor.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=320321"}],"version-history":[{"count":0,"href":"https:\/\/fivemor.com\/index.php?rest_route=\/wp\/v2\/posts\/320321\/revisions"}],"wp:attachment":[{"href":"https:\/\/fivemor.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=320321"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/fivemor.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=320321"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/fivemor.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=320321"},{"taxonomy":"dealstore","embeddable":true,"href":"https:\/\/fivemor.com\/index.php?rest_route=%2Fwp%2Fv2%2Fdealstore&post=320321"},{"taxonomy":"offerexpiration","embeddable":true,"href":"https:\/\/fivemor.com\/index.php?rest_route=%2Fwp%2Fv2%2Fofferexpiration&post=320321"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}